1. Home
  2. DH vs AKBA Comparison

DH vs AKBA Comparison

Compare DH & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DH
  • AKBA
  • Stock Information
  • Founded
  • DH 2011
  • AKBA 2007
  • Country
  • DH United States
  • AKBA United States
  • Employees
  • DH N/A
  • AKBA N/A
  • Industry
  • DH Computer Software: Prepackaged Software
  • AKBA Biotechnology: Pharmaceutical Preparations
  • Sector
  • DH Technology
  • AKBA Health Care
  • Exchange
  • DH Nasdaq
  • AKBA Nasdaq
  • Market Cap
  • DH 310.5M
  • AKBA 336.2M
  • IPO Year
  • DH 2021
  • AKBA 2014
  • Fundamental
  • Price
  • DH $2.79
  • AKBA $1.93
  • Analyst Decision
  • DH Hold
  • AKBA Strong Buy
  • Analyst Count
  • DH 11
  • AKBA 3
  • Target Price
  • DH $5.35
  • AKBA $6.50
  • AVG Volume (30 Days)
  • DH 986.1K
  • AKBA 6.1M
  • Earning Date
  • DH 05-06-2025
  • AKBA 05-08-2025
  • Dividend Yield
  • DH N/A
  • AKBA N/A
  • EPS Growth
  • DH N/A
  • AKBA N/A
  • EPS
  • DH N/A
  • AKBA N/A
  • Revenue
  • DH $252,202,000.00
  • AKBA $160,180,000.00
  • Revenue This Year
  • DH N/A
  • AKBA $23.40
  • Revenue Next Year
  • DH $3.26
  • AKBA $58.44
  • P/E Ratio
  • DH N/A
  • AKBA N/A
  • Revenue Growth
  • DH 0.31
  • AKBA N/A
  • 52 Week Low
  • DH $2.54
  • AKBA $0.80
  • 52 Week High
  • DH $8.33
  • AKBA $2.89
  • Technical
  • Relative Strength Index (RSI)
  • DH 36.94
  • AKBA 46.74
  • Support Level
  • DH $2.87
  • AKBA $1.83
  • Resistance Level
  • DH $2.99
  • AKBA $1.99
  • Average True Range (ATR)
  • DH 0.17
  • AKBA 0.19
  • MACD
  • DH 0.07
  • AKBA -0.03
  • Stochastic Oscillator
  • DH 47.62
  • AKBA 15.42

About DH Definitive Healthcare Corp.

Definitive Healthcare Corp is a provider of healthcare commercial intelligence. Its SaaS-based healthcare commercial intelligence platform is designed to provide comprehensive and accurate information on the healthcare ecosystem in the U.S. The platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers, and improving win rates with detailed contextual information. The company derives substantially all of its revenue from the sale of subscription fees for access to its platform and stand-ready support. Geographically, it derives a majority of its revenue from the United States.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Share on Social Networks: